In the News

Sep 14, 2026

Vyome appoints Jerry Leonard as Chief Financial Officer

Jul 1, 2026

Vyome receives Chinese patent for acne treatment formulation

May 28, 2026

Vyome Advances VT-1953 Toward Pivotal Stage with FDA Filings and $5.3M Capital Raise

May 14, 2026

Tata group’s Impetis out-licenses arthritis and autoimmune drugs to Vyome

May 13, 2026

Tata-backed Impetis licenses JAK inhibitor assets to Vyome Holdings

May 12, 2026

Vyome Secures Exclusive License for JAK Inhibitors, Targeting $57B Market

Apr 28, 2026

The next big opportunity lies in immune and rare disease white spaces

Mar 30, 2026

Vyome Holdings Q4 2025 Earnings Call Highlights

Mar 26, 2026

Vyome Posts Strong Phase 2 Data for VT-1953, Eyes $1B Market Opportunity

Mar 10, 2026

Targeted incentives for innovation-driven research would further strengthen India’s biotech ecosystem